Contact
Please use this form to send email to PR contact of this press release:
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
TO:
Please use this form to send email to PR contact of this press release:
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
TO: